According to Zacks, “Collplant holdings Ltd is a regenerative medicine company focused on 3D bioprinting of tissues and organs. It involved in developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. It product pipeline include rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs, Vergenix line of rhCollagen products includes a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote a rapid optimal healing of acute and chronic wounds. Collplant holdings Ltd is based in NESS-ZIONA, Israel. “
Separately, HC Wainwright initiated coverage on COLLPLANT HOLDI/S in a report on Tuesday, December 18th. They set a “buy” rating and a $7.00 price objective for the company.
CLGN traded down $0.04 during midday trading on Monday, reaching $5.29. 2,309 shares of the company were exchanged, compared to its average volume of 3,305. The firm has a market capitalization of $20.20 million, a P/E ratio of -9.61 and a beta of 2.32. COLLPLANT HOLDI/S has a one year low of $3.13 and a one year high of $8.73.
About COLLPLANT HOLDI/S
CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, dermal fillers for aesthetics, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe.
Further Reading: The Role of a Fiduciary and Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for COLLPLANT HOLDI/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COLLPLANT HOLDI/S and related companies with MarketBeat.com's FREE daily email newsletter.